"Our technology and data capabilities help researchers and providers gain insights into health inequities and support strategies and solutions to advance health equity."
CEO, PRESIDENT AND CO-FOUNDER, INCOG BIOPHARMA SERVICES
"Wrapping up Q1 in 2023 we are now above 80 employees with a facility that is cGMP production ready and actively manufacturing commercial PPQ batches for one of our biopharma clients."
"Among our customers, we note a heightened awareness of preventative safety practices. Also, OURAY see a lot of growth in those exceedingly hazardous chemicals such as fluoridated and brominated materials."
HEAD OF DRUG SUBSTANCE (SR), HEAD OF DRUG DELIVERY & PRODUCT (PS), EVONIK HEALTH CARE
"The US leads innovation, so if you are not heavily invested there in pharma, you are in trouble. Lots of our clients are shifting their production from Asia, so the US will remain critical to Evonik Health Care’s growth."
"We want to pioneer a commodity utility approach for needed areas of pharmaceutical manufacturing, and make that available as a sustainable platform that any country can start with and innovate from."
"Experienced CDMOs can provide companies with access to new formulation and technology methods that improve the bioavailability of difficult-to-formulate compounds."
"Companies should be ready to address hostile short-selling and unsolicited takeover bids, develop rapid responses to special meetings and activist demands, and vigorously engage with institutional shareholders, proxy advisory firms, and potential regulators."
"The expansion will allow Prince to more than double its headcount, increase manufacturing capacity, and offer additional ready-to-use products and sterilization services to the market."
This pre-release, containing insights from executives across leading African upstream, downstream, financing, and service providers, spotlights developments in local capabilities, infrastructure, and new projects that are driving change in some of Africa's most interesting oil and gas producing countries.